Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Higher costs extend GW Pharmaceuticals losses

Higher costs extend GW Pharmaceuticals losses

Shares in GW Pharmaceuticals (LON:GWP) took a knock as the British drug maker blamed higher research and development for steeper full-year losses.

The company, which develops medicines using cannabis extracts, spent £43.5mln on testing and other product development activities in the year to September, a £10.8mln increase on last year.

The spending spree widened pre-tax losses to £19.6mln over the twelve months, which is nearly double last year’s loss of £10.4mln. 

GW and its investors have been pumping money into advancing Epidiolex, a drug program in the field of childhood epilepsy.

Justin Gover, GW's chief executive said he expects to complete much of the Epidiolex development program by 2015 as well as start to build a US commercial presence in anticipation of future launch.

Clinical trials are set to be completed by the middle of 2016 and launch the drug in early 2017.

The firm’s flagship product is its cannabinoid prescription drug Sativex, which is approved in 27 countries outside the US to treat spasticity due to multiple sclerosis.

Sativex is in phase three clinical development as a potential treatment of pain linked to advanced cancer.

 

Total revenue climbed to £30mln, up from £27.3mln. Sativex product sales revenues totalled £4.4mln.

 

Cover added that the company is looking to progress multiple clinical trials for its cannabinoid product pipeline. 

 

Shares were 20p lower at 372p, a drop of 5%.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

Laboratory testing
October 09 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
cannabis leaf and green tablets
October 29 2018
The company will now proceed with stage II of the human clinical trial.
Cannabis leaf
Fri
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use